Figure 2.
Ki67 and DLX2 are predictive biomarkers of disease progression risk in prostate cancer.Kaplan–Meier plots demonstrating (A) prostate-specific cancer death over time according to Ki67 score. (B) metastasis development over time according to Ki67 score. (C) prostate-specific cancer death over time according to DLX2 score. (D) metastasis development over time according to DLX2 score.